adalimumab — CareFirst (Caremark)
immunotherapy-related inflammatory arthritis (immune checkpoint inhibitor-related toxicity)
Initial criteria
- Member is using requested medication for immunotherapy-related inflammatory arthritis
Reauthorization criteria
- Member achieves or maintains a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition
Approval duration
12 months